UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2010
QUANTRX BIOMEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
Nevada | 0-17119 | 33-0202574 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
100 S. Main Street, Suite 300
Doylestown, Pennsylvania 18901
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (267) 880-1595
Not applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective April 30, 2010, the Board of Directors of QuantRx Biomedical Corporation (the Company) elected and appointed Patrick T. Mooney, M.D. and Robert G. Pinco to fill the vacancy left by the death of Dr. Arthur Hull Hayes, Jr. and an additional vacancy on the Board.
Dr. Arthur Hull Hayes, Jr., passed away February 11, 2010. Dr. Hayes served as a Director of the Company since September 2006, and also served as the Chairman of the Compensation Committee.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |
99.1 | Joint Press Release, dated May 6, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
QUANTRX BIOMEDICAL CORPORATION | ||
Dated: May 6, 2010 | By: | /s/ Walter Witoshkin |
Name: Walter Witoshkin | ||
Title: Chairman and Chief Executive Officer |